A new treatment is available for people (≥ 12 years old) who have mild-to-moderate COVID-19 AND are at high risk of COVID-19 complications (eg, they have coexisting conditions and/ or they are elderly). The monoclonal antibodies, amlanivimab plus etesevimab, received emergency use authorization (EUA) based on the BLAZE-1 trial. In this study of 1,035 people with mild-tomoderate COVID-19, a single infusion significantly reduced hospitalization and all-cause death by about 70% compared with placebo. During the 29 days of follow-up, 11 (2%) of the participants treated with the combination were hospitalized, compared with 36 (7%) given placebo. There were no deaths in the treatment group compared with 10 deaths in the placebo group.
This EUA gives clinicians an additional COVID-19 treatment option. Another combination of monoclonal antibodies (casirivimab and imdevimab) from Regeneron received EUA in November 2020 for the same indication. Note that these combinations are not authorized for patients who are already hospitalized due to COVID-19 or who require oxygen therapy due to COVID- 19. Their use may lead to worse clinical outcomes when administered to hospitalized patients.
Like what you’re seeing? Click here to subscribe to The Rx Consultant today! Use promo code 40%DISCOUNT for 40% off!